Clascoterone (Breezula): The First New Hair Loss Drug in 30 Years

The last genuinely new mechanism for male pattern baldness reached the market in 1997: finasteride. For nearly three decades since, every man treating hair loss has worked with the same two tools, minoxidil and finasteride. That is about to change. In December 2025, a drug called clascoterone completed the largest Phase 3 trial program ever run for a topical hair loss treatment.

By Radiance360 · Pharmacist-Formulated · 2026

The quick answer

What is clascoterone? A topical solution (Breezula) that blocks DHT directly at the follicle receptor without reducing DHT levels in the rest of the body. It is the first genuinely new hair loss mechanism in over 30 years.

Does it work? In two Phase 3 trials with 1,465 men, both met their primary endpoint: a 539% relative hair-count improvement over placebo in one, 168% in the other, pooled over 252%.

When will it be available? Phase 3 is complete. FDA and EU submissions are expected early 2027, earliest launch around mid-2027. Not available anywhere yet.

Is it safer than finasteride? Its side effect profile in trials was comparable to placebo, with no systemic hormonal effects. That is its main advantage over finasteride.

Why Clascoterone Is a Genuinely New Approach

To understand why this matters, understand how the two existing treatments work and what they cannot do.

Finasteride reduces DHT production throughout the body by blocking the enzyme that converts testosterone into DHT. It works, but because it affects DHT everywhere, it carries a risk of systemic side effects. Minoxidil does not touch DHT; it improves blood flow to the follicle.

Clascoterone does something neither does. It blocks the androgen receptor directly at the scalp: DHT is still produced normally, but clascoterone occupies the follicle receptor before DHT can reach it, shielding it from the signal that drives miniaturisation. Finasteride reduces the hormone everywhere; clascoterone blocks its signal only where applied. The minoxidil vs finasteride guide covers the mechanisms it improves upon.

Finasteride turns down DHT for your whole body to protect your scalp. Clascoterone leaves your body's DHT alone and locks the door at the follicle. Same goal, a far more targeted route.

The Same Drug Already Has an FDA Track Record

One detail gives clascoterone unusual credibility: its active ingredient is already FDA-approved and widely used.

Clascoterone 1% cream was approved in 2020 as Winlevi for acne, where it blocks skin androgen receptors to reduce oil production. It has since become one of the most prescribed topical acne treatments in the US, meaning the molecule already has years of real-world safety data at a lower concentration.

The hair loss version, Breezula, uses a 5% topical solution formulated for scalp absorption. The higher concentration is why you cannot use the acne product on your scalp and expect results.

What the Phase 3 Results Actually Showed

Here is the verified data, along with the context needed to read it correctly.

Cosmo Pharmaceuticals ran two identical Phase 3 trials, SCALP 1 and SCALP 2, enrolling 1,465 men across 51 sites in the US and Europe, the largest such program ever run for a topical male hair loss treatment. Both met their primary endpoint in Target-Area Hair Count: one showed a 539% relative improvement over placebo, the other 168%, with a pooled improvement over 252% (p less than 0.05).

Those percentages need careful reading. A 539% relative improvement does not mean hair count rose 539%; it means the clascoterone group grew that much more than placebo in the target area, and because placebo groups often show minimal change, relative figures look dramatic. In absolute terms, clascoterone produced roughly 14 hairs per square centimetre versus the 20 or more that finasteride delivers. Its raw regrowth is somewhat less; its advantage is a cleaner side effect profile.

In April 2026, Cosmo reported positive 12-month data confirming long-term safety, continued efficacy, and the mechanism holding up over time, with a safety profile comparable to placebo and no systemic androgen effects.

The Real Advantage: Side Effects

The reason clascoterone matters is not that it makes hair grow more than finasteride. On raw numbers, it grows slightly less. It matters because of who it helps.

Many men avoid finasteride over concern about its potential sexual and hormonal side effects. Those concerns, discussed in the finasteride side effects guide, keep many from an effective treatment. Because clascoterone does not lower DHT systemically, it does not carry the same mechanism for those effects; in trials, adverse events matched placebo.

This makes clascoterone potentially transformative for one group: men who need DHT blockade but cannot or will not take finasteride. It is exactly the "maximum benefit, minimum side effect" direction the whole field is moving toward.

When Will Clascoterone Be Available?

This is the question most people searching for clascoterone want answered.

Phase 3 is complete; the 12-month safety follow-up finished in spring 2026. Cosmo plans parallel FDA and EU submissions, with the US submission targeted for early 2027 and the earliest possible launch around mid-2027. That timeline has slipped before over the drug's nearly two-decade development, so mid-2027 is the optimistic case.

For Pakistan, add the usual lag: new treatments typically arrive three to five years after initial US or European approval, if at all. Realistically, clascoterone is a 2028-and-beyond consideration here. It cannot be bought anywhere today.

What This Means If You Are Losing Hair Now

Clascoterone is the most promising near-term development in hair loss treatment, and still at least a year from any market and years from Pakistan. Waiting is not a strategy: the follicles it could one day protect are best preserved by treating them now.

For active hair loss today, the proven approach remains minoxidil plus finasteride, delivered together in the hair fall solution range at verified concentrations. Men concerned about finasteride side effects, the exact concern clascoterone solves, should read the topical vs oral finasteride guide, since topical finasteride already cuts systemic exposure significantly.

The full hair care range is built for the long view: preserve what you have now, so when treatments like clascoterone arrive, there is still a follicle for them to work on.

Frequently Asked Questions

What is clascoterone? Clascoterone is a topical solution, brand name Breezula, that blocks DHT at the hair follicle receptor without reducing DHT elsewhere in the body. The same active is already FDA-approved for acne as Winlevi. The 5% hair loss version completed Phase 3 in late 2025.

When will clascoterone be available? Phase 3 is complete. FDA and EU submissions are expected in early 2027, with the earliest possible launch around mid-2027. Pakistan would follow several years later. It cannot be purchased anywhere today.

Is clascoterone better than finasteride? On raw regrowth, finasteride delivers somewhat more, around 20 hairs per square centimetre versus roughly 14. Clascoterone's advantage is its cleaner side effect profile, because it does not lower DHT systemically. For men who cannot tolerate finasteride, it may be the better option.

Kya clascoterone Pakistan mein milta hai? Nahi. Clascoterone abhi kisi bhi mulk mein available nahi hai. FDA submission early 2027 mein expected hai, launch mid-2027 se pehle mumkin nahi. Pakistan tak pahunchne mein kaafi saal aur lagenge. Filhaal proven treatment, jaise minoxidil aur finasteride, hi use karna chahiye.

Kya clascoterone finasteride se zyada safe hai? Trials mein iske side effects placebo ke barabar the, aur koi systemic hormonal effect nahi tha. Kyunke yeh DHT ko sirf scalp par block karta hai, poore body mein nahi, is liye finasteride wale sexual ya mood side effects ka risk mechanism mojood nahi. Un mardon ke liye jo finasteride nahi le sakte, yeh behtar option ho sakta hai.

To Sum Up

Clascoterone is the first genuinely new hair loss mechanism in over 30 years. It blocks DHT at the scalp receptor without touching the body's overall DHT levels, and its Phase 3 trials in 1,465 men confirmed both meaningful hair growth and a side effect profile comparable to placebo.

It grows slightly less hair than finasteride in absolute terms, but that was never the point. It offers effective DHT blockade to the many men who avoid finasteride out of fear of systemic side effects. That is a real advance. It is also not available yet, will not launch before mid-2027 at the earliest, and is years from Pakistan. The treatment that helps you this year is still the one that already exists, and using it now keeps your follicles ready for what comes next.

Hair Fall Solution Collection | Full Hair Care Range | Topical vs Oral Finasteride Guide